Equine Rhinopneumonitis-Influenza Vaccine
For the vaccination of healthy,
susceptible horses 6 months of age or older, including pregnant mares, as an aid
in the reduction of respiratory diseases caused by equine herpesvirus type 1
(EHV-1) and type 4 (EHV-4), and by equine influenza virus types A2 North
American and A2 Eurasian.
Administration and Dosage:
Shake well before use.
Using aseptic technique, inoculate horses intramuscularly with a 2 mL dose.
Administer a second 2 mL dose intramuscularly in 3-4 weeks using a different
injection site. Administer a third 2 mL dose in 3-4 weeks by either the
intramuscular or intranasal route. Revaccinate annually and prior to anticipated
exposure, by either the intramuscular or intranasal route.
For Veterinary Use Only
Store at 35-45°F (2-7°C). Protect from
freezing. Do not vaccinate within 21 days before slaughter. Anaphylactoid
reactions may occur following use. Antidote: Epinephrine.
This product has been tested under laboratory conditions and
shown to meet all Federal standards for safety and efficacy in normal, healthy,
immunocompetent animals. This level of performance may be affected by conditions
such as stress, weather, nutrition, disease, parasitism, other treatments,
individual idiosyncrasies, or impaired immunological competency. These factors
should be considered by the user when evaluating product performance or freedom